BriMindInvest Logo

Envista Holdings Corporation (NVST) Stock Analysis 2026

HealthcareMedical Instruments & Supplies
$27.80
as of 2026-08-26

BriMind AI Score

Proprietary
25
Weak
Price CAGR
-0.4%
1Y Return
+25.2%
Analyst Upside
+12.4%
Rev Growth
7.1%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$28.39+2.1% potential
Bear Case
$20.98
Bull Case
$39.12
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

NVST Revenue & Profitability Breakdown

This chart shows how NVST's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$2.86B
Cost of Revenue
-$1.26B
Gross Profit
$1.60B55.9% margin
Operating Expenses
-$1.25B
Operating Income
$346.1M12.1% margin
Tax & Other
-$251.1M
Net Income
$95.0M3.3% margin
Gross Margin
55.9%
Operating Margin
12.1%
Net Margin
3.3%
EBITDA Margin
10.8%

Key Financial Metrics

Envista Holdings Corporation trades at a trailing P/E of 46.90x, generates $275.8M in free cash flow, runs a debt/equity ratio of 51.62, and converts shareholder equity into profit at a 3.1% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$4.37B
Enterprise Value
$3.66B
P/E (Trailing)
46.90
P/E (Forward)
16.31
EV / EBITDA
13.57
Price / Sales
1.27
Price / Book
1.06
Revenue
$2.86B
Revenue Growth
7.1%
Earnings Growth
111.3%
EBITDA
$269.6M
Gross Margin
55.9%
Operating Margin
12.1%
Net Margin
3.3%
Return on Equity
3.1%
Return on Assets
3.4%
Free Cash Flow
$275.8M
Total Cash
$1.08B
Total Debt
$1.56B
Debt / Equity
51.62
Current Ratio
2.42
Quick Ratio
1.94
Beta
0.86
Dividend Yield
None
Payout Ratio
0.0%
Book Value / Share
$19.16

Wall Street Analyst Consensus

12 analysts covering Envista Holdings Corporation currently lean toward a Hold rating, with a mean 12-month price target of $30.57 (+10.0% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingHold(12 analysts)
SellStrong Buy
Low Target$15.00-46.0%
Mean Target$30.57+10.0% upside
High Target$24.00+-13.7%

Intrinsic Value Estimates for NVST

Across the 1 valuation model available for NVST, fair value estimates range from $34.17 to $34.17, averaging $34.17 — above the current $27.80 price. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DCF Model (10yr)
$34.17
+22.9% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
Fair Value Range
$34.17 – $34.17
Average Estimate
$34.17
Potential Upside
22.9%

⚠️ Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Compare NVST with Peers

NVST vs DHREnvista Holdings vs Danaher — Dental Products vs Life S
STVN vs NVSTStevanato vs Envista — Drug Containment vs Dental Techn

Unlock the Full NVST Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis